PLoS ONE (Jan 2015)

Houttuynia cordata targets the beginning stage of herpes simplex virus infection.

  • Pei-Yun Hung,
  • Bing-Ching Ho,
  • Szu-Yuan Lee,
  • Sui-Yuan Chang,
  • Chuan-Liang Kao,
  • Shoei-Sheng Lee,
  • Chun-Nan Lee

DOI
https://doi.org/10.1371/journal.pone.0115475
Journal volume & issue
Vol. 10, no. 2
p. e0115475

Abstract

Read online

Herpes simplex virus (HSV), a common latent virus in humans, causes certain severe diseases. Extensive use of acyclovir (ACV) results in the development of drug-resistant HSV strains, hence, there is an urgent need to develop new drugs to treat HSV infection. Houttuynia cordata (H. cordata), a natural herbal medicine, has been reported to exhibit anti-HSV effects which is partly NF-κB-dependent. However, the molecular mechanisms by which H. cordata inhibits HSV infection are not elucidated thoroughly. Here, we report that H. cordata water extracts (HCWEs) inhibit the infection of HSV-1, HSV-2, and acyclovir-resistant HSV-1 mainly via blocking viral binding and penetration in the beginning of infection. HCWEs also suppress HSV replication. Furthermore, HCWEs attenuate the first-wave of NF-κB activation, which is essential for viral gene expressions. Further analysis of six compounds in HCWEs revealed that quercetin and isoquercitrin inhibit NF-κB activation and additionally, quercetin also has an inhibitory effect on viral entry. These results indicate that HCWEs can inhibit HSV infection through multiple mechanisms and could be a potential lead for development of new drugs for treating HSV.